-
Sarepta's Upside Story Is Just Getting Started
Monday, October 2, 2017 - 11:01am | 334Read More...Analysts at Morgan Stanley conducted a tracking survey to gain a better understanding of Sarepta Therapeutics Inc (NASDAQ: SRPT)'s outlook for its Exondys 51 therapy. After coming away with encouraging data, the firm's David Lebowitz upgraded Sarepta's stock rating from Equal Weight to Overweight...
-
Why Did Sarepta Therapeutics Plunge 20%?
Thursday, June 2, 2016 - 11:26am | 347Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 20 percent on Thursday after reports surfaced that the U.S. Food and Drug Administration may pressure the company to provide its Duchenne muscular dystrophy patients with at-cost access to its eteplirsen therapy on a "...
-
PTC Therapeutics Spikes 40% After Translarna Update In England
Friday, April 15, 2016 - 1:45pm | 364Read More...Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company that focuses on therapeutics that target post-transcriptional control processes, surged higher by more than 40 percent Friday afternoon. Investors and traders were reacting to the company's announcement that the...
